Stay updated on A(B)VD+Nivolumab in Frontline for HL Clinical Trial
Sign up to get notified when there's something new on the A(B)VD+Nivolumab in Frontline for HL Clinical Trial page.

Latest updates to the A(B)VD+Nivolumab in Frontline for HL Clinical Trial page
- Check6 days agoChange DetectedRevision label updated to v3.4.3 from v3.4.2.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedUpdates shown are limited to changes in the study record's date entries (new dates such as 2026-02-17, 2026-02-13, 2027-01, 2026-02 and deletions like 2025-11-20, 2026-01, 2025-11-19, 2025-11), with no changes to study design, eligibility, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check34 days agoChange DetectedRevision metadata updated to v3.4.2. The earlier maintenance notice about government funding lapse and the v3.4.1 revision were removed.SummaryDifference0.4%

- Check41 days agoChange DetectedAn updated site-wide notice about government funding lapse and NIH Clinical Center operations was added, with a link to opm.gov for status updates. A new Revision: v3.4.1 replaces the previous v3.4.0.SummaryDifference0.4%

- Check48 days agoChange DetectedGlossary toggle added and metadata expanded with additional MeSH terms and related keywords (e.g., Nivolumab, Doxorubicin, Vinblastine, Bleomycin, Dacarbazine). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference63%

- Check62 days agoChange DetectedA new revision label Revision: v3.3.4 was added, replacing Revision: v3.3.3. This appears to be a minor site maintenance update and does not affect study information.SummaryDifference0.0%

Stay in the know with updates to A(B)VD+Nivolumab in Frontline for HL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the A(B)VD+Nivolumab in Frontline for HL Clinical Trial page.